News

March 2021 -

Foundation for Neglected Disease Research (FNDR), Bangalore, India, has been awarded funding from the Cystic Fibrosis Foundation for preclinical development of a novel bactericidal therapeutic that has the potential to treat non-tuberculous mycobacterial (NTM) infections in people with cystic fibrosis (CF). The novel molecule is jointly owned by FNDR and National Centre for Polar and Ocean Research (NCPOR), Goa, India. Dr. Shridhar Narayanan, CEO of FNDR, said “FNDR is proud to be the first Indian organization to receive a drug development award funding from the CF Foundation. We remain committed to discovering and developing new and better cures for infectious diseases.”

September 2019 -

Foundation for Neglected Disease Research is happy to announce that its partner TB Alliance has completed the Phase 1 clinical trial of TBA-7371, a novel DprE1 inhibitor, for the treatment of tuberculosis. Its partner Bill & Melinda Gates Medical Research Institute is initating Phase 2a trial - "A dose escalation, randomized study to evaluate safety, early bactericidal activity (EBA) and pharmacokinetics of TBA-7371 in adult patients with rifampicin-sensitive pulmonary tuberculosis". With no pre-existing resistance or cross-resistance with other TB drugs, TBA-7371 could have significant potential in the treatment of TB.

February 2018 –

FNDR won the Economic Times Power of Ideas 2017 Award in March 2018. This award is made by Economic Times and Facebook in partnership with Department of Science & Technology (DST), Government of India and the Centre for Innovation Incubation and Entrepreneurship (CIIE), IIM Ahmedabad. This is India’s largest entrepreneurship development program, given to start ups with promising ideas and a spirit of innovation. FNDR won the award for its diagnostics program in Tuberculosis.

October 2017 -

Foundation for Neglected Disease Research is happy to announce that its partner, TB Alliance has initiated the Phase 1 clinical trial of TBA-7371, a novel DprE1 inhibitor, for the treatment of tuberculosis. With no pre-existing resistance or cross-resistance with other TB drugs, TBA-7371 could have significant potential in the treatment of TB.